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ABSTRACT 
BACKGROUND:  Direct-to-consmner advertising (DTCA) of medications, a mar- 
keting tool used by the pharmaceurical industry to increase patient awareness of prod- 
ucts, affects both consumer behavior and, ukimately, physician prescribing practices. 
Billions of dollars are budgeted each year for DTCA, and its influence is far-reaching. 
However, little information is available about patient-initiated physician interactions in
which television-based DTCA has played a role in consumer behavior. 
OBJECT IVE:  The objective of this study was to explore the influence of television- 
based DTCA on treatment changes in patient-initiated medication use. 
METHODS:  A 68-item survey instrument consisting of dichotomous, multiple- 
choice, and open-ended questions was constructed and sent to a convenience sample 
of US residents during 3 consecutive months ending in February 2005. The survey, 
which was accessed through an Internet link provided in the e-mail, was designed to 
capture data about patient perceptions and behaviors regarding television-based 
DTCA of prescription medications used for seasonal allergy and asthma as well as 
demographic infbrmation. Inferential and descriptive analyses were performed. Key 
tests included Crosstabs analysis and normal approximation to the binomial test with 
the z score. 
RESULTS:  Surveys were sent to 2500 individuals. A total of 427 valid surveys 
were returned for a 17.1% response rate. Of the 402 respondents (94.1%,) who stated 
that they had seen DTCA for seasonal allergy medication, 50 (12.4%) said they had 
discussed the advertised medication with their physician and 22 of those discussions 
(44.0%) resulted in a change in treatment. Three hundred forty-two respondents 
(80.1%) stated that they had viewed DTCA for prescription asthma medications, and 
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23 of those respondents (6.7%) said that they had discussed the brand of asthma 
medication viewed on television with their physician. Those discussions resulted in a 
change in treatment for 9 respondents (39.1%). 
CONCt .USlON:  Within this l imited, self-reported, survey sample, patient- 
initiated discussions with physicians regarding television-based DTCA of allergy and 
asthma medications resulted in a change of treatment in 44.0% and 39.1% of respon- 
dents, respectively. (Cuff TherRes C/iel Exp. 2008;69:130 141) g) 2008 Excerpta Medica 
Inc. 
KEY WORDS:  direct-to-consumer advertising, allergy, asthma, pharmaceutical 
industry, survey, television advertising. 
INTRODUCTION 
Direct-to-consumer advertising (DTCA) impacts both consumers and providers of 
health care. These advertisements are divided into 3 categories: help-seeking adver- 
tisements, which contain information about a specific condition without mentioning 
a specific medication; product-claim advertisements, which include product name, 
therapeutic use, and safety information; and reminder advertisements, which contain 
only a product name. 1 Physicians generally prefer help-seeking advertisements be- 
cause that type of advertisement does not suggest a specific medication choice. In 
fact, the American College of Physicians (ACP) released aposition paper on the topic 
that encouraged the pharmaceutical industry to increase the use of help-seeking adver- 
tisements. 2 The ACP paper highlighted the desirability of advertisements that advise 
patients to see their physician while reinforcing that the decision about appropriate 
medication treatment lies with the physician. Research indicates that >40.0% of 
physicians feel DTCA benefits patients by creating abasis for better patient physician 
discussions and by making patients more aware of treatment options. However, ap- 
proximately one fifth of physicians feel that DTCA can create problems, such as in- 
creased numbers of requests for prescriptions when nonpharmacologic interventions 
are more appropriate or increased time needed uring an office visit to correct patient 
misconceptions due to DTCA. 3 
A literature search was conducted of MEDLINE, EMBASE, and Google Scholar 
without limits on years or language using the following terms: consumer  advef¢/;slllg, 
DTCA, difect-lo-cowume# adveftisivg, teJevisiole advertisivg, and hedustry advertising. Key 
words were truncated when appropriate to broaden the search. In a study of 78 physi- 
cians and 1431 patients performed concurrently in physicians' offices in Sacramento, 
California, and Vancouver, British Columbia, Mintzes et al 4 administered a physician 
patient-paired survey after office visits to determine the impact of DTCA on patient 
medication requests and physician prescribing activities. The authors found that 
patients who requested an advertised medication had a 50% higher rate of receiving 
the requested medication than patients who requested a nonadvertised medication. 
They also found that of the 12% of patients who specifically requested a medication 
from their prescriber, 42% of the requests were for a product advertised to consumers. 
Furthermore, the study found that when a patient requested a DTCA medication, physi- 
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cians indicated they were ambivalent about the choice of medication being prescribed 
approximately half the time. In another study 5using the same survey data, the authors 
found that patients who requested DTCA medications were more likely to receive 
> 1 new prescription than those patients who did not request DTCA medications. 
To explore the relationship between dollars spent on DTCA for prescription medi- 
cations and the resulting responses about consumer behavior to the advertised product, 
Robinson et al ~ conducted a mail survey of 523 Colorado physicians and 261 physi- 
cians nationwide and a telephone survey of 500 Colorado households asking them to 
rate their agreement with statements concerning DTCA. Physicians in general had a 
negative view of DTCA, feeling that not enough information was provided regarding 
product cost (98.7%), adverse vents (54.8%), and alternative disease management 
options (94.7%). Additionally > 80.0gh of physicians believed that DTCA led patients 
to request specific medications. Almost all of the households surveyed (99.2%) reported 
seeing DTCA, of which 29.0% felt that DTCA was a positive trend in health care and 
13.3% indicated that DTCA had led them to request a specific medication from their 
physician. 
Datti and Carter 7 conducted an analysis to determine the influence of DTCA on 
requests for medication f?om older patients (aged >75 years). They determined that, 
of 2601 respondents who had been exposed to DTCA, 801 (30.8%) requested a pre- 
scription from their physician and 556 (69.4%) received the requested prescription. 
However, the study did not capture data to determine if the requested medication was 
the one for which patients had viewed DTCA. Additionally, the authors did not indi- 
cate the form of DTCA that was viewed. 
In a 2003 study by Murray et al, s the authors explored a number of aspects of 
DTCA influence, including physician patient relationships, psychosocial benefits, 
and clinical benefits and harms by surveying >3200 patients. The authors found that 
of the 161 people who requested an intervention (eg, a medication change, laboratory 
test, or specialist referral), 131 (81.4%) received a change in medication. Again, this 
study did not report whether the request was directly due to DTCA or if the change 
in medication was to the DTCA product. 
While all of these studies explored the influence of DTCA on patients and physicians, 
they did not specifically examine the impact hat television advertising has on consumer 
behavior. Additionally they were administered by mail or telephone, resulting in the 
selection of different segments of the population. In this study we assessed the direct 
role that DTCA via television plays on patient-initiated prescription requests and con- 
sequent physician prescribing of advertised medications. We also selected a patient 
population that uses the Internet by administering the survey online. Compared with 
individuals who do not use the Internet, those who do, especially those who search for 
health information, rend to be more educated, affluent, health-oriented, and more 
directly involved with their own health care decision making. 9,1° 
SUBJECTS AND METHODS 
This study design used the survey-questionnaire r search method, with emphasis on 
quantitative analysis. The design was based on a 1-group, after-only procedure. The 
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subjects included a convenience sample of 2500 US residents aged > 18 years with 
e-mail addresses from AOL, Hotmail, MSN, Road Runner, and Yahoo. Survey infor- 
mation was collected for 3 consecutive months ending in February 2005. 
The study design was approved by the University of Louisian~Monroe institu- 
tional review board, Monroe, Louisiana. Subjects accessed an introductory Web site 
containing information about the research with a link to the study. All responder data 
were deidentified. Linking to the survey was considered providing informed consent 
as per the approved protocol. 
Respondents completed a 68-item online survey. Face validity of the author- 
developed questionnaire was established by panel review and a small pilot study 
with colleagues of the researchers completing the survey and critiquing the items. 
The survey instrument was assessed using the Cronbach C~; the internal standardized 
reliability for the 11 items on the importance of drug information within DTCA 
yielded a value of 0.91, indicating a high degree of correlation. The survey ques- 
tions solicited information in the following categories: demographic characteristics; 
medication use; television viewing involving prescription medication advertise- 
ments; actions taken in response to televised advertisements; discussion of medica- 
tions with physicians prompted by advertisements; and whether the discussions re- 
suited in a change of medication. Medications in the seasonal allergy and asthma 
categories were included in this study because they accounted for a significant portion 
of DTCA dollars during the survey time frame. M Table 112 14 displays the DTCA 
dollars associated with 4 of the study medications and how spending changed over 
the course of 3 years. 
Patients were queried regarding use of and familiarity with the following 
medications: allergy Allegra®, * Clarinex®, ~ and Zyrtec®~; asthm~Adva i r®,  § 
Singulair®, II and Flovent®. § Information was also collected regarding use of, and 
familiarity with, the fictitious prescription medications Fyzol and Zoltaine as an 
additional means to determine reliability and validity of the survey instrument. 
STAT IST ICAL  ANALYS IS  
Descriptive statistics were used to summarize tile responses to tile survey items 
and to determine factors such as change in treatment. The data were analyzed using 
the normal approximation to the binomial test with z scores, frequency counts, and 
Crosstabs using SPSS 13.0 (SPSS, Inc., Chicago, Illinois) and SAS 8.1 (SAS Institute 
Inc., Cary, North Carolina). Each category resulted in 3 binomial tests (eg, medica- 
tions in the allergy category were tested including the following possible respon- 
dent selections: Allegra, Clarinex, and Zyrtec). The same testing was applied to the 
asthma medication choices. 
*Trademark of sanofi-aventis, Bridgewater, New Jersey. 
* Trademark of Schering-Plough Corp., Kenilworth, New Jerse> 
¢ Trademark of Pfizer Inc., New York, New York. 
§ Trademark of GlaxoSmithKline, Philadelphia, Pennsylvania 
I! Trademark of Merck & Co. Inc., Whitehouse SEation, New Jersey 
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Table I. Direct-to-consumer advertising (DTCA) spending on seasonal allergy and asthma 
medications. ~2-~4 All data are in millions of US $. 
DTCA 
Medication Manufacturer 2003 2004 2005 
Advair Diskus ® 
(fluticasone/salmeterol) 
Allegra ® (fexofenadine) 
Singulair ® (montelukast) 
Zyrtec ® (cetirizine) 
GlaxoSmithKline 101.7 92.8 136.9 
Philadelphia, Pennsylvania 
sanofi-aventis 125.5 99.7 NA 
Bridgewater, New Jersey 
Merck & Co. Inc. 130.5 108.1 105.1 
Whitehouse Station, New Jersey 
Pfizer US Pharmaceutical Group 105.3 104.7 NA 
New York, New "fork 
RESULTS 
SAMPLE CHARACTERIST ICS  
From a convenience sample of 2500 US Internet users, 487 individuals responded 
to the study survey. Fifty-one surveys were eliminated ue to inconsistencies or 
> 10% incompleteness and/or input error and 9 surveys were excluded because the 
responders esided outside of the United States. The final usable sample yielded 427 re- 
spondents, for a 17.1% response rate. The sample included 299 women (70.0%) and 
128 men (30.0%). Most respondents (173 [40.5%]) were aged 35 to 49 years. One 
hundred nine of the respondents (25.5 %) were aged >50 years. Two hundred eighty-two 
respondents (66.0%) reported incomes >$40,000, and 369 (86.4%) reported having 
at least some college education. The demographic characteristics of the respondents 
are shown in Table I I .  
PRESCRiPT iON ALLERGY MEDiCAT iONS 
One hundred six of the 427 respondents (24.8%) were taking a prescription sea- 
sonal allergy medication (Allegra, Clarinex, or Zyrtec) at the time they completed the 
survey (Figure 1). Of the 402 individuals (94.1%) who stated that they had seen 
DTCA for seasonal allergy medication, 50 (12.4%) said they had discussed the adver- 
tised medication with their physician and 22 (44.0%) of these discussions were 
reported to be directly responsible for a change in treatment. No respondents stated 
that they were taking the [ictitious allergy drug, Fyzol, at the time they completed 
the survey, but 7 respondents (1.6%) stated they had seen an advertisement for it. 
PRESCRIPT ION ASTHMA MEDiCAT iONS 
Thirty respondents (7.0%) indicated that they were using asthma medication at 
the time they completed the survey (Figure 2). Three hundred forty-two of the 
respondents (80.1%) stated that they had viewed television-based DTCA for prescrip- 
tion asthma medications. Of these, 23 respondents (6.7%) said that they had dis- 
cussed the brand of asthma medication viewed on television with their physician, and 
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Table II. Demographic characterist ics of the survey respondents 
(N = 427) .  
Characteristic No. (%) 
Sex 
Female 299 (70.01 
Male 128 130,01 
Age range, y 
18-34 145 (34.0) 
35-49 173 (40.5) 
50-65 91 (21.3) 
>65 18 (4.2) 
Race/ethnicity 
White, non-Hispanic 355 (83.1) 
Black, non-Hispanic 43 (10.1) 
Asian or Pacific Islander 10 (2.3) 
Hispanic or Latino 8 (1.9) 
Native American 2 (0.5) 
Unknown, other 9 (2.1) 
Education level 
High school or less 58 (13.6) 
Some college 126 (29.5) 
College degree 134 (31.4) 
Graduate/professional degree 109 (25.5) 
Household income, 2005 US $ 
<12,000 17 (4.0) 
12,000-24,999 40 (9.4) 
25,000-39,999 88 (20.6) 
40,000-59,999 98 (23.0) 
_>60,000 184 (43.1) 
SeMeported health status 
Excellent 74 (17.3) 
Very good 178 (41.7) 
Good 127 (29.7) 
Fair 39 (9.1) 
Poor 9 (2.1) 
Insurance coverage 352 (82.4) 
Method of prescription payment 
Patient paid full cost 73 (17.1) 
Patient paid partial cost 310 (72.6) 
Insurance paid full cost 44 (10.3) 
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Do you take a prescription medication for seasonal allergies? (n = 427) I 
I 
I m l m  
YES NO 
(n = 106 [24,8%]) (n = 321 [75,2%]) 
J 
-Which brand do you normally take? Select one, 
AIlegra ®* 43 (40.6%) 
Clarinex®! 23 (21.7%) 
Zyrtec®¢ 40 (37.7%) 
Fyzol~ 0 
Other 0 
I Have you seen a TV advertisement tor a seasonal allergy medication? (n = 427) ] 
I 
J m  m l  
YES NO 
(n = 402 [94,1%]) (n = 25 [5,9%]) 
~ Jldentify these medications. Select one or more. ] 
J 
Allegra ®* 368 (91,5%) 
Clarinex®t 278 (69.2%) 
Zyrtec ®e 291 (72.4%) 
Fyzol§ 7 (1.6%) 
Other 0 
I 
1 
Did you discuss the brand of medication viewed on TV with your physician? (n = 402) / 
/ 
I 
J i 
YES NO 
(n = 50 [12.4%]) (n = 352 [87,6%]) 
I 
Did physician consultation result in either the addition or, or change to, the 
requested medication? 
I 
m J  I 
YES NO 
(n = 22 [44,0%]) (n = 28 [56,0%]) 
Figure 1. Self-reported impact of allergy medication direct-to-consumer advertising on 
patient-initiated change in treatment in a convenience sample of US resi- 
dents. *Trademark of sanofi-aventis, Bridgewater, New Jersey; tTrademark 
of Schering-PIough Corp., Kenilworth, New Jersey; +Trademark of Pfizer US 
Pharmaceutical Group, New York, New York; §Fictitious drug name. 
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L Do you take a prescription medication for asthma? (N = 427) ] 
I 
r 1 
YES NO 
(n = 30 [7,0%]) (n = 397 [93.0%]) 
-IWhich brand do you normally take? Select one. I 
Advair ®* 11 (36.7%) 
Singulair®t 11 (36.7%) 
FIovent ® * 5 (16.7%) 
Zoltaine¢ 0 
Other 3 (10.0%) 
Have you seen a an (N = 427) /  
/ 
TV advertisement tor asthma medication? 
1 
J 
F 1 m 
YES NO 
(n = 342 [80.1%]) (n = 85 [19.9%]) 
± 
-Identify these medications. Select one or more. / 
1 
/ 
Advair ®* 237 (69,3%) 
Singulair®t 271 (79.2%) 
FIovent ® * 143 (41.8%) 
Zoltaine¢ 19 (5.6%) 
Other 0 
I q 
Did you discuss the brand of medication viewed on TV with your physician? (n = 342) / 
/ 
I 
F m  L 
YES NO 
(n = 23 [6.7%]) (n = 319 [93.3%]) 
Did physician consultation result in either the addition of, or change to, the 
requested medication? 
I __L_  --L 
YES J F NO 
(n = 9 [39.1%]) (n = 14 [60.9%]) 
Figure 2. Self=reported impact of asthma medication direct-to-consumer advertising on 
patient-initiated change in treatment in a convenience sample of US residents. 
*Trademark of GlaxoSmithKline, Philadelphia, Pennsylvania; tTrademark of Merck 
& Co. inc., Whitehouse Station, New Jersey; +Fictitious drug name. 
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this discussion was reported to have resulted in a change in treatment in 9 respondents 
(39.1%). No respondents stated that they were taking the fictitious asthma medica- 
tion, Zoltaine, at the time they completed the survey; however, 19 of the respondents 
(5.6%) stated they had seen an advertisement for it. 
METHOD OF PAYMENT FOR PRESCRIPT ION P4ED|CAT|ONS 
Seventy-three of the respondents (17.1%) reported paying full cost for their pre- 
scription medications, 310 (72.6%) reported being responsible for part of their pre- 
scription costs, and 44 (10.3%) reported their prescription costs were paid for in full 
by their insurance company (Table I1). Of the 73 reported patient-initiated physician 
communications (50 allergy, 23 asthma), 32.9% were initiated by patients who paid 
the full cost of their medications, 52.1% by patients who paid part of their medication 
costs, and 15.1% by patients whose medications were paid in full by their insurance 
company. 
D|SCUSS|ON 
Most medications listed in the survey were recognized by the respondents, and few of 
them reported they had seen DTCA for the fictitious allergy (1.7 %) or asthma (5.6%) 
medication, indicating that responses were generally reliable. This consmner ecall 
ability reinforces research indicating that consumers may be influenced by repeated 
exposure to advertisements. Our study did not take into account he other sources of 
DTCA that consumers may come into contact with on a regular basis, such as Internet 
and print advertisements. DTCA via television, however, might especially impact the 
American consumer, since the average American views -16 hours of televised pre- 
scription medicine advertisements per year. 15 
Additionally, pharmaceutical manufacturers invest substantial amounts of money 
in their product advertisements. In 2004, more than $4 billion was spent on DTCA, 
with $3.7 billion of that targeted to television advertising. 16Several researchers found 
a positive correlation between spending on DTCA for specific targeted medications 
and increased sales of those advertised products. 17 20 It is estimated that for every 
10% increase in DTCA spending there is a 1% increase in drug sales and that for each 
dollar spent on direct advertising companies gain up to $6 in sales. 21 One study found 
that for every $1000 spent in the United States on DTCA for allergy medication, an 
additional 24 prescriptions were written for that specific medication. 17
Researchers at the National Institute for Health Care Management found that 
increased sales of the 50 drugs with the largest advertising budgets accounted for 47.8% 
of the $20.8 billion increase in retail spending on prescription drugs in the United 
States from 1999 to 2000. The remaining percentage increase was a result of increased 
sales o f -9880 medicines. 22 This ability to motivate consumers to ask for advertised 
medications, and thus increase sales, is why pharmaceutical companies dedicate the 
majority of their DTCA budget o a small number of lucrative medications. Over time 
the industry has continued to focus their advertising influence on only a small mmlber 
of drugs. In 2001, 10 drugs made up 36% of all DTCA spending and in 2005 the top 
20 DTCA drugs accounted for > 50% of all spending on DTCA. 21,23 
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When evaluating the responses for allergy medications, it is interesting to note 
that ahnost all (94.1%) responders recalled seeing an advertisement ~br these medi- 
cations. Perhaps due to this fact, recall did not appear to be significantly affected by 
the manufacturer DTCA expenditures. Even though the amount spent for Zyrtec 
advertising in 2003 totaled US $105.3 million and the amount spent for Clarinex 
in 2003 was substantially more US ($129.2 million), there was a minimal difference 
in the number of respondents who reported seeing an advertisement for each of 
these medications. 24However, this survey did not solicit information about how 
many advertisements the respondents had seen for each medication. Although only 
12.4% of responders who saw the advertisements spoke with their physician about 
the product seen in the advertisement, almost half (44.0%) of those experienced a 
change in prescribed treatment. This may reflect the physician-reported pressure to 
fill patient requests. 4 We acknowledge that these changes in treatment could have 
been arrived at independent of the patient intervention, and it is unclear if all of the 
requests that resulted in a change of treatment could be attributed solely to the 
patient-initiated physician discussion. 
A comparatively small number of responders were taking prescription asthma 
medications versus those taking medications for seasonal allergy. Thus, the size of the 
asthma subgroup made it more difficult to draw definitive conclusions. However, of 
the 6.7% of the asthma group who reported talking with their physician about medi- 
cations seen in advertisements, 39.1% reported a change in drug treatment. 
Of the respondents who reported speaking to their physician about a DTCA medi- 
cation (n 73), 67.1% had some form of prescription coverage. Because advertising 
dollars are typically spent for brand-name, nongeneric medications, it is possible that 
patients with full or partial coverage are more likely to request DTCA drugs than 
patients who self-pay the entire cost of their prescriptions. Patients who have personal 
financial obligation for their drug costs may not be willing to initiate an intervention 
that could result in a prescription for a more expensive brand-name medication. 
Overall, this sample of survey respondents was more affluent, educated, and health- 
oriented than the general population, findings that are consistent for Internet users, 
as reported in the literature. 9,24,25 By using an Intemet-based survey instrument, we 
sampled an unexplored patient pool and provided insight into their behaviors involving 
DTCA medications and patient-initiated physician communications. Understanding 
the influence that television-based DTCA might have on the medication usage prac- 
tices of this specific population can help guide both health care providers in making 
appropriate prescribing decisions about DTCA medication requests at the point of 
care and industry in planning where to effectively spend their DTCA money. 
STUDY L IMITAT IONS 
The use of a specific list of disease states and drug treatments may not reflect the 
experiences of all patients, limiting generalizations to other patients or disease states. 
Also, DTCA expenditures for 2003 were used to select he included medications and 
the survey occurred in 2004 to 2005, so changes in DTCA expenditures by drug 
might have impacted the selection of medications in a particular class. 
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Due to a low response rate, the number  of respondents who u l t imately  dis- 
cussed a DTCA medicat ion with their physician was small. This small number  
may not truly reflect the influence that DTCA has on the larger populat ion and, 
as such, the results cannot be general ized. Also, it may be more l ikely for a pat ient  
to later recall and report  v iewing DTCA for a medicat ion for which a prescr ipt ion 
was previously requested, thus potent ia l ly  introducing report ing or recall bias to 
the results. 
Administering the survey via the Internet resulted in a self-selected convenience 
sample of respondents. Our survey attracted a strong majority of female responders 
(70.0%,), which was not consistent with national gender usage data for the Internet. 26 
Gender differences are usually not commonly  found, with the highest proport ion of 
female users in the mid-At lant ic  region (54/~_~). 27This gender disparity may have 
had an impact on our results. However, our f indings were similar to those of other 
studies 4 s that assessed behavior after exposure to print or nonspecific DTCA, making 
this less of a concern. 
CONCLUSION 
With in  this l imited, self-reported, survey sample, patient- init iated iscussions with 
physicians regarding television-based DTCA of allergy and asthma medications 
resulted in a change of treatment in 44.0% and 39.1% of respondents, respectively. 
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